RE:TLRY's sequential growth in the export business (~40%)Savage97 wrote: Generating $7.8 million in sales. TLRY is well-placed in Europe, due to its production, distribution infrastructure and established brands. $$$
TipRanks / Pablo However, maybe of more significance, the company is making headway in the international space. Zuanic is “positively impressed” with the export business’ sequential growth.
International Sales climbed QoQ from $10.3 million to $13.7 million, with $7.8 million in sales from markets outside EMEA. The company now sells product to 20 different countries, including the key market of Germany, where Tilray holds the #1 position in the medical segment, boasting a ~20% share.
“As European countries start to legalize cannabis in the next few years (Germany by late 2023?),” says Zuanic, “We believe TLRY is well-placed given its production and distribution infrastructure, and established brands (especially in med tinctures).”
29% QoQ growth in Australia. Pharmacies are specifically requesting Tilray's Product by name.... (from Qtr report conference call - Denise)